Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-

Part of paid clinical trials in Englewood, New Jersey.

Sponsor
Englewood Hospital and Medical Center
Study ID
NCT06937996
Status
Recruiting
Apply to this trial

Conditions

  • Pancreatic Cancer Non-resectable

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • NanoKnife — DEVICE
    The NanoKnife, System has been commercially available since 2009, and is FDA-approved to treat soft tissue tumors. The NanoKnife System has received FDA clearance for the surgical ablation of soft tissue. It has not received clearance for the therapy or treatment of any specific disease or condition.

Study Details

The purpose of this study is to evaluate the short and intermediate term safety of the NanoKnife Irreversible Electroporation System when used off-label to treat unresectable pancreatic cancer. In addition, the study will evaluate the efficacy of this device in treating pain associated with unresectable pancreatic cancer. Quality of life post-procedure will also be collected.

Key Dates

Start date
May 13, 2025
Status verified
Jun 2025
Primary completion
May 31, 2035
Completion
May 31, 2035

Study Design

Enrollment
25 participants (estimated)

Primary Outcome Measure

Safety and Pain [ Time Frame: 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Englewood HospitalEnglewoodNew Jersey07631
Jamie Ketas
[email protected]
201-894-3418

Find similar trials in Englewood, NJ

By research site
Englewood Hospital· Englewood, NJ

Related Studies